Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TELO Stock Forecast 2026-2027
$1.32
Current Price
$45.38M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TELO Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
TELO Price Momentum
+5.6%
1 Week Change
+21.1%
1 Month Change
-71.2%
1 Year Change
-0.8%
Year-to-Date Change
-75.6%
From 52W High of $5.40
+25.7%
From 52W Low of $1.05
📊 TOP ANALYST CALLS
Did TELO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Telomir is one of their latest high-conviction picks.
Latest TELO Stock Price Targets & Analyst Predictions
TELO has shown a year-to-date change of -0.8% and a 1-year change of -71.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for TELO. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TELO Analyst Ratings
0
Buy
0
Hold
0
Sell
TELO Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.32
Latest TELO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TELO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Telomir Pharmaceuticals Inc. (TELO) Competitors
The following stocks are similar to Telomir based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Telomir Pharmaceuticals Inc. (TELO) Financial Data
Telomir Pharmaceuticals Inc. has a market capitalization of $45.38M with a P/E ratio of -2.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -303.2%.
Valuation Metrics
Market Cap
$45.38M
Enterprise Value
$38.15M
P/E Ratio
-2.3x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+16.1%
Current Ratio
17.5x
Debt/Equity
1.3x
ROE
-303.2%
ROA
-167.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Telomir Pharmaceuticals Inc. (TELO) Business Model
About Telomir Pharmaceuticals Inc.
What They Do
Develops innovative therapies for oncology and autoimmune diseases.
Business Model
The company focuses on research and development of advanced medicines, generating revenue by bringing new therapies to market. It operates a robust pipeline of drug candidates at various clinical trial stages and collaborates with leading medical institutions to enhance its drug development processes.
Additional Information
Telomir Pharmaceuticals Inc. is positioned in the biopharmaceutical sector, which is crucial for addressing complex diseases. Its emphasis on precision medicine and targeted approaches highlights its commitment to improving patient outcomes and shaping future healthcare innovations.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1
CEO
Mr. Erez Aminov
Country
United States
IPO Year
N/A
Website
telomirpharma.comTelomir Pharmaceuticals Inc. (TELO) Latest News & Analysis
Latest News
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) reports that its compound Telomir-1 effectively induces tumor cell death in various subtypes of triple-negative breast cancer, confirming a mechanistic action.
Why It Matters
Telomir Pharmaceuticals' positive data on Telomir-1's effectiveness against triple-negative breast cancer could enhance its market position and attract investment, indicating potential for future growth.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals (NASDAQ: TELO) reported preclinical results showing Telomir-Zn affects metal balance linked to oxidative stress and genomic integrity, advancing its cancer and aging therapies.
Why It Matters
Telomir's findings on Telomir-Zn's role in metal balance and cellular health could signal potential breakthroughs in cancer and aging therapies, impacting future valuations and investor interest.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) reported significant tumor growth and spread reduction in TNBC animal models with its compound Telomir-1, indicating potential therapeutic efficacy.
Why It Matters
Telomir-1's significant efficacy in TNBC models suggests potential for breakthroughs in cancer treatment, which could enhance Telomir Pharmaceuticals' market value and attract investor interest.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals reported positive results from GLP toxicology studies for its lead candidate, Telomir-1, showing no treatment-related toxicity and consistent systemic exposure.
Why It Matters
Positive results from toxicology studies enhance Telomir's credibility and potential for successful drug development, likely boosting investor confidence and stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals (NASDAQ: TELO) reported that its candidate Telomir-1 reduced PSA levels in prostate cancer cells, indicating potential effectiveness in treatment response.
Why It Matters
The reduction of PSA levels by Telomir-1 indicates potential efficacy in prostate cancer treatment, which could enhance Telomir's market position and attract investor interest.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) reports that its compound Telomir-1 shows efficacy against aggressive leukemia cells, expanding its oncology profile beyond previous cancer types.
Why It Matters
The expansion of Telomir-1's oncology profile to blood cancers, along with its efficacy in other aggressive cancers, enhances Telomir Pharmaceuticals' growth potential and market attractiveness.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About TELO Stock
What is Telomir Pharmaceuticals Inc.'s (TELO) stock forecast for 2026?
Analyst forecasts for Telomir Pharmaceuticals Inc. (TELO) are not currently available. The stock is trading at $1.32.
Is TELO stock a good investment in 2026?
Analyst ratings for TELO are not currently available. The stock is currently trading at $1.32. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TELO stock?
Price predictions from Wall Street analysts for TELO are not currently available. The stock is trading at $1.32.
What is Telomir Pharmaceuticals Inc.'s business model?
The company focuses on research and development of advanced medicines, generating revenue by bringing new therapies to market. It operates a robust pipeline of drug candidates at various clinical trial stages and collaborates with leading medical institutions to enhance its drug development processes.
What is the highest forecasted price for TELO Telomir Pharmaceuticals Inc.?
Price targets from Wall Street analysts for TELO are not currently available. The stock is trading at $1.32.
What is the lowest forecasted price for TELO Telomir Pharmaceuticals Inc.?
Price targets from Wall Street analysts for TELO are not currently available. The stock is trading at $1.32.
What is the overall TELO consensus from analysts for Telomir Pharmaceuticals Inc.?
Analyst ratings for TELO are not currently available. The stock is trading at $1.32.
How accurate are TELO stock price projections?
Stock price projections, including those for Telomir Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 8:38 AM UTC